X4 Pharmaceuticals, Inc. XFOR
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) is a hematology drug developer. Its lead program, mavorixafor (X4P-001), is in Phase 3 for primary chronic neutropenia (PCN). Its next catalyst on record is mavorixafor - 4WARD trial: Complete enrollment (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: mavorixafor - 4WARD trial — Complete enrollment (2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| mavorixafor (X4P-001) - PCN | primary chronic neutropenia (congenital, acquired autoimmune, or idiopathic) | small molecule | Phase 3 |
| mavorixafor - G-CSF dose reduction in PCN | primary chronic neutropenia | small molecule | Phase 2 |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 hematology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.